Core Viewpoint - The company is actively engaging with investors and stakeholders to discuss its product developments, market strategies, and future growth prospects, particularly in the PVP product line and high-margin offerings like Euriz. Group 1: PVP Product Insights - The prices of PVP series products are expected to gradually recover in 2026 after a period of high margins due to the European energy crisis and the Russia-Ukraine conflict, which had previously inflated raw material costs [3] - The company anticipates that PVP product sales will enter an upward trend based on market demand and supply dynamics [3] Group 2: New Energy and Photovoltaic Applications - In the new energy battery sector, PVP is utilized as a dispersant for carbon nanotubes, with sales projected to reach approximately 4,000 tons in 2025, expecting a 20% increase in 2026 [4] - In the photovoltaic sector, PVP serves as a key surfactant/dispersant for spherical silver powder, which is crucial for silver paste printing performance and battery efficiency, with 2025 shipments estimated at 200 tons and continued growth expected in 2026 [4] Group 3: Euriz Product Advantages - Euriz (ethylene-vinyl ether/maleic anhydride copolymer) is a high-value product with a high price per ton and a gross margin of approximately 60-70%, with an expected shipment volume of around 900 tons in 2025 [5] - The company is the only manufacturer globally using a non-benzene process for Euriz production, creating a significant technical barrier and is actively seeking partnerships to enhance market presence [5] Group 4: Shareholder Communication and Equity Structure - The company emphasizes effective communication with shareholders and has reached consensus with its top ten shareholders on operational and governance matters [6] - The major shareholder plans to increase their stake in the company by liquidating some personal assets, aiming to optimize the equity structure and stabilize control [6] Group 5: Medical Sector Developments - The company has invested in five cell and gene therapy enterprises, with several products progressing well in their development stages, including one product entering NDA approval and others in clinical trials [7] - Some of these enterprises are positioned to potentially achieve NDA approval and initiate IPOs, with the company collaborating closely with them for market promotion and commercialization [7] Group 6: Strategic Transformation Goals - The company is transitioning from a capacity-led approach to a focus on technology and service leadership, with plans to establish itself as a global leader in functional chemicals by 2025-2027 [8]

Group 1: Investor Relations Activity - The investor relations activity included a meeting with analysts and representatives from various financial institutions [2][3] - Key participants included analysts from New Fortune Magazine, Shenwan Hongyuan Securities, and several private equity funds [2][3] Group 2: Company Overview and Product Insights - The company is focused on PVP series products, which experienced price increases due to the European energy crisis and the Russia-Ukraine conflict, but is expected to stabilize in 2026 [3][4] - In 2025, the company sold approximately 4,000 tons of PVP products in the new energy sector, with a projected 20% increase in 2026 [4] - The company also sold about 200 tons of PVP products in the photovoltaic industry in 2025, with expected growth in 2026 [4] Group 3: Product Development and Strategic Goals - The company is transitioning from "capacity leading" to "technology leading + service leading" as part of its strategic upgrade plan initiated in 2025 [4][5] - The company is the only manufacturer using a non-benzene process for producing its products, which provides a competitive edge [5] Group 4: Shareholder Communication and Equity Structure - The company emphasizes shareholder communication and has engaged with its top ten shareholders regarding operational and governance matters [6][7] - The controlling shareholder and their associates are optimistic about the company's long-term prospects and have intentions to increase their shareholding [7] Group 5: Medical Sector Investments - The company has strategically invested in five biotechnology firms focusing on innovative drug development, with several products advancing through regulatory stages [6][7] - One product is in the NDA approval stage, two are in Phase II clinical trials, and several others have received IND approvals in China and the U.S. [7]

Financial Performance - In 2024, the company achieved operating revenue of 1,606.32 million yuan, a year-on-year increase of 1.45% [2] - The net profit attributable to the parent company was 349.68 million yuan, a decrease of 29.07% compared to the previous year [2] - Earnings per share were 0.73 yuan, down 30.48% year-on-year, primarily due to a decline in gross profit from high polymer products [3] - In Q1 2025, operating revenue was 324.86 million yuan, a decrease of 17.69% year-on-year [3] - The net profit attributable to the parent company for Q1 2025 was 80.42 million yuan, down 33.75% year-on-year, with earnings per share at 0.17 yuan, a decrease of 32.00% [3] Product Applications - PVP is used in the new energy sector as a dispersant for carbon nanotubes and in solid-state batteries for material dispersion and interface optimization [3] - In 2024, the expected shipment volume for new energy applications is over 3,000 tons, with a projected increase in 2025 [3] - PVP's application in electronic skin focuses on material modification and conductive network construction, with no large-scale shipments currently [4] Pricing and Market Impact - PVP prices have significantly decreased compared to the previous two years and are currently stabilizing [4] - The company anticipates an increase in average product prices as the proportion of high-end products rises [4] - Approximately 50% of PVP exports are to Europe, the Middle East, Southeast Asia, and India, with exports to the U.S. accounting for only 3%-5% [5] Product Overview - Euriz is a copolymer of vinyl ether/maleic anhydride, known for its linear molecular structure and good chemical stability [5] - In 2024, Euriz sales are expected to reach about 1,500 tons, with approximately 90% for export and a high unit price [5] - The estimated shipment volume for Euriz in 2025 is over 2,000 tons, with a gross profit margin of 60-70% [5]

Core Viewpoint - The company has reported its annual financial results, highlighting its main business areas in fine chemicals and precision medicine, along with a proposed cash dividend distribution to shareholders [1][25]. Company Overview - The company specializes in fine chemicals and precision medicine, being the first in China to focus on the production, research, and sales of PVP series products and PVME/MA series products [5][25]. - The main products include PVP, which is widely used in pharmaceuticals, food processing, cosmetics, new energy, environmental water treatment, and other industrial fields [6][20]. Financial Highlights - The company has proposed a cash dividend of 2.5 yuan per 10 shares (including tax) based on a total of 484,700,005 shares, with no stock bonus [4][31]. - The company has undergone a change in its auditing firm to Zhongqin Wanxin Certified Public Accountants [3]. Business Applications - PVP products are utilized in various sectors: - **Pharmaceuticals**: Used as binders, stabilizers, and release agents in drug formulations [6][7]. - **Food Processing**: Acts as a clarifying agent and stabilizer [8][9]. - **Cosmetics**: Functions as a thickening agent and moisture-retaining agent [10][11]. - **New Energy**: Serves as a dispersant in lithium batteries and enhances photovoltaic cell efficiency [12][13]. - **Environmental Treatment**: Used in membrane materials and as inhibitors in gas transportation [14][15]. - **Other Industries**: Improves the performance of coatings, inks, textiles, and paper [16][18][19]. Strategic Developments - The company has approved investments in two entities, increasing its stake in Huadao Biological and Zhongqi Huiyun Technology [29]. - The company is focusing on expanding its precision medicine services, leveraging its technology in equipment, reagents, and medical services [24].

Investment Rating - The report does not explicitly provide an investment rating for the chemical products industry or the specific company being analyzed [1]. Core Insights - The company primarily operates in fine chemicals and precision medical businesses, with fine chemicals accounting for approximately 90% of its operations, while precision medical business remains relatively small [18]. - The production capacity for PVP is constrained by the upstream NVP monomer, with a current release capacity of 20,000 tons per year, and future adjustments will be made based on market sales [18]. - PVP products have seen price adjustments due to market conditions, with an average gross margin of around 50% prior to the third quarter of 2023 [18]. - In the renewable energy sector, PVP is utilized as a dispersant for carbon nanotubes and is expected to see sales of over 3,000 tons in 2024, with anticipated growth in 2025 [18]. - The company’s product, Eurysia, is a copolymer with a high gross margin of 60-70%, and sales are projected to increase in 2025 [19]. - Approximately 50% of PVP products are exported, with Europe, the Middle East, and South Asia being the primary markets [20]. - The chemical sector aims to optimize product structure and increase the proportion of high-end products, while the medical sector focuses on enhancing existing technologies and deepening collaborations with innovative medical companies [20]. Summary by Sections 1. Basic Research Information - The research was conducted on the company New Open Source in the chemical products industry on February 27, 2025 [13]. 2. Detailed Research Institutions - The research was conducted by institutions including GF Securities, with representatives present during the meeting [16]. 3. Research Institution Proportion - The report does not provide specific data on the proportion of research institutions involved [17]. 4. Main Content Information - The company’s operations are primarily in fine chemicals and precision medical fields, with a focus on PVP and Eurysia products, and plans for future growth in both sectors [18][19][20].

Group 1: Company Overview - The company primarily operates in fine chemicals and precision medical businesses, with fine chemicals accounting for approximately 90% of its operations, while precision medical business remains relatively small [2]. - The 2024 performance data is still under audit, with the official report expected in April 2025 [2]. Group 2: PVP Production and Pricing - PVP production capacity is limited to 20,000 tons per year due to constraints from downstream polymerization capabilities [3]. - The average price of PVP products has adjusted year-on-year due to market conditions, with industrial-grade PVP experiencing significant price fluctuations, stabilizing before the third quarter [3]. Group 3: PVP in New Energy Sector - In 2024, the company sold over 3,000 tons of PVP in the new energy sector, with expectations for growth in 2025 based on future orders [3]. Group 4: Eurysia Product Insights - Eurysia, a copolymer of vinyl ether/maleic anhydride, is expected to see sales of approximately 1,500 tons in 2024, with a high unit price and a gross margin of 60-70% [3]. - An increase in shipment volume is anticipated for 2025 [3]. Group 5: Export and Market Distribution - Approximately 50% of PVP products are exported, with Europe, the Middle East, and South Asia as primary markets; the U.S. market accounts for only 3-5% [3]. Group 6: Future Development Plans - The chemical sector aims to optimize product structure and increase the proportion of high-end products, with new PVP polymerization capacity being developed to match upstream NVP capacity [4]. - The medical sector will focus on enhancing existing product technology and deepening collaborations with innovative drug companies to tap into the potential of precision medical business [4].